Novonesis achieves 100% renewable electricity across global operations

DENMARK – Novonesis has achieved its 2025 milestone target of securing that 100% of all the electricity used in global operations is renewable. We received the official recognition from the organization RE100 in late January. 

The company achieved its renewable electricity target by working with partners to identify and secure supply to all sites globally with a focus on wind and solar projects.

Its diversified renewable energy portfolio includes on-site solar, waste-to-biogas, renewable electricity certificates, and other energy projects across our sites.

“At Novonesis, we believe business growth, people and planet stewardship go hand in hand. We are excited to reach this milestone, made possible by continuous efforts of many colleagues to improve energy efficiency throughout production as well as procuring renewable electricity.

“The RE100 stamp builds trust in our company and solidifies that biosolutions are becoming an ever stronger tool for our customers to reimagine how to build a stronger and more profitable business, fit for the future,” said Thomas Bomhoff, VP for Global Sustainability & External Engagement. 

This milestone is part of the company’s ongoing efforts to build resilience and make a positive impact on people and the planet.

Securing renewable electricity across sites is part of the broader climate targets and ambition to achieve Net Zero by 2050, and to reduce GHG emissions from Scopes 1 and 2 by 65% by 2025 and 75% by 2030 compared to our 2018 baseline.

RE100 is a global corporate renewable energy initiative bringing together hundreds of large and ambitious businesses committed to 100% renewable electricity. Over 400 companies have made a commitment to go ‘100% renewable’.

Novonesis reports 8% sales growth in first nine months of 2025

Recently, the company delivered 8% organic sales growth in the first nine months of 2025, with the Full-year outlook narrowed upwards to 7-8%, from 6-8% previously.

Strong broad-based organic sales growth of 8%, including the negative impact of exiting certain countries of 1 percentage point. Price contributed by 1 percentage point (Q3: ~1 percentage point).

Food & Health at 9% organic sales growth including the negative impact of exiting certain countries of 2 percentage points. Planetary Health at 8% organic sales growth.

Emerging Markets at 12% organic sales growth, Developed Markets at 6% organic sales growth (Q3: 4%).

Adjusted EBITDA margin at 37.3%, up by 130 bps (Q3: down by 30 bps). including significant currency headwinds. Adjusted net profit increased by 22%.

NIBD/EBITDA at 2.0x, and free cash flow before acquisitions at EUR 668.4 million (Q3: EUR 361.3 million).

Subscribe to receive our email newsletters with the latest news and insights from Africa, Middle East and around the world. SUBSCRIBE HERE